Skip to main content
SpringerLink
Log in

Healthy Bones After Menopause: What Has to Be Done?

  • Chapter
  • First Online:
Pre-Menopause, Menopause and Beyond

Part of the book series: ISGE Series ((ISGE))

  • 1266 Accesses

Abstract

Osteoporosis leads to weakness of the skeleton and increased risk of fracture. The World Health Organisation (WHO) has defined Osteoporosis as a systemic skeletal disease characterised by low bone mass and micro architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.

The likelihood of a major fracture at any of the four major sites (spine, femoral neck, wrist, proximal humerus) is 40% or more in developed countries, a figure close to the probability of coronary heart disease. In a woman at the menopause, the remaining lifetime probability after a fracture at any one of these sites is less favourable that the one after breast cancer. All preventive measures must be individualized and tailored according to the personal risk profile including personal and family history and the results of relevant investigations as well as to the woman’s preferences and expectations. Prescription of MHT or SERMs for primary prevention of fragility fractures should be part of an overall strategy including lifestyle recommendations regarding diet, a sufficient daily intake calcium and proteins, adequate Vit. D levels, exercise, smoking cessation and safe levels of alcohol consumption. The evidence presented by the WHI study does not support the restrictions placed on MHT as a bone-specific drug. Healthy women younger than 60 years and/or less than 10 years from menopause should not be unduly concerned about the safety profile of a correctly indicated MHT.

Nitrogen-containing bisphosphonates have been proven in numerous randomized, controlled outcome trials (RCTs) in postmenopausal osteoporosis to reduce significantly the incidence of fragility fractures. They are suitable first-line treatments for elderly women after the age of 60 years with postmenopausal osteoporosis. In women with low fracture risk, a “drug holiday” after 5–10 years of bisphosphonate treatment has been recommended. Serious adverse effects such as atypical subtrochanteric fracture and osteonecrosis of the jaw are very rare in women receiving bisphosphonates for fracture prevention in presence of postmenopausal osteoporosis, and not for oncological indications.

Adherence may be insufficient in some patients treated by oral drugs. In these patients, the administration of non-oral bisphosphonates or denusomab are recommended. Denosumab is a humanized monoclonal antibody that works by decreasing the activity of the receptor activator of nuclear factor kappa B ligand. In contrast to bisphophonates, denosumab has a short half-life so that its antiresorptive effects as well as its adverse effects are rapidly reversible. Denosumab reduces median bone formation rate to zero after 2-3 years use. Continuous use of denosumab to 8 years maintains the reduced fracture rates. The relative risk of serious adverse events is low. Again, osteonecrosis of the jaw has only been seen in cancer patients receiving very high doses of denosumab. EMA recommended in 2014 that strontium ranelate should only be used for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

Parathyroid hormone (PTH[1-84]) and human recombinant PTH[1-34] (Teriparatide) are the only anabolic agents available today. They reduce the risk of new vertebral and non-vertebral fractures in postmenopausal women with and without prior fractures. With sequential PTH treatment, BMD gain is maintained or increased by alendronate or raloxifene, but lost if parathyroid hormone or teriparatide is not followed by an antiresorptive agent.

In conclusion, MHT is the first choice for fracture prevention in women < 60 years and/or less than 10 years from menopause. In women with a simultaneously increased breast cancer risk, SERMs should be preferred. In women aged 60 years or more, non-hormonal anti-resorptive therapies such as bisphosphonates or denosumab are the first choice. For economic reasons, teriparatide is reserved for the treatment of severe osteoporosis. If costs are considered without taking into account adherence, to-day, some older bisphosphonates have the best cost-benefit ratio. Following the recommendation of EMA, Strontium ranelate should only be used for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733

    Article  CAS  PubMed  Google Scholar 

  2. Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243–248

    Article  CAS  PubMed  Google Scholar 

  3. Kanis JA, Johnell O, Oden A, De Laet C, Malstrom D (2004) Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 75:90–99

    Article  CAS  PubMed  Google Scholar 

  4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 843)

    Google Scholar 

  5. Office of the Surgeon General (US) (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD

    Google Scholar 

  6. Schwenkglenks M, Lippuner K, Hauselmann HJ, Szucs TD (2005) A model of osteoporosis impact in Switzerland 2000–2020. Osteoporos Int 16:659–6571

    Article  PubMed  Google Scholar 

  7. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131–1140

    Article  CAS  PubMed  Google Scholar 

  8. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A et al (2000) Long-term risk of osteoporotic fracture in Malmø. Osteoporosis Int 11:669–674

    Article  CAS  Google Scholar 

  9. Melton LJ III, Kallmes DF (2006) Epidemiology of vertebral fractures: implications for vertebral augmentation. Acad Radiol 13:538–545

    Article  PubMed  Google Scholar 

  10. Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiologically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800

    Article  CAS  PubMed  Google Scholar 

  11. EPOS Group (2002) Incidence of vertebral fracture in Europe: results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17:716–724

    Article  Google Scholar 

  12. EPOS Group (2002) Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis Int 13:565–5671

    Article  Google Scholar 

  13. Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 2:285–289

    Article  CAS  Google Scholar 

  14. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018

    Article  CAS  PubMed  Google Scholar 

  15. Cummings SR, Melton JR III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  16. Empfehlungen 2015 zur Prävention, Diagnostik und Therapie der Osteoporose. SVGO/ASCO 2015, http://www.svgo.ch/content/inhalt_deutsch/inhalt/broschueren/broschueren.html

  17. Kanis JA, EV MC, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteop Int 24:23–57

    Article  CAS  Google Scholar 

  18. Birkhäuser M (2013) Präventionskonzepte und aktuelle Therapieempfehlungen in der Peri- und Postmenopause. UNI-MED Verlag AG Bremen, London, Boston

    Google Scholar 

  19. Lips P, Vitamin D (2007) Status and nutrition in Europe and Asia. 13th workshop on vitamin D (Victoria, British Columbia, Canada, April 2006). J Steroid Biochem Mol Biol 203:620–625

    Article  Google Scholar 

  20. Bischoff-Ferrari HA, Can U, Staehelin HB et al (2008) Severe vitamin D deficiency in Swiss hip fracture patients. Bone 42(3):597–602

    Article  CAS  PubMed  Google Scholar 

  21. Bischoff-Ferrari HA et al (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116(9):634–639

    Article  CAS  PubMed  Google Scholar 

  22. Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR (2008) Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 149(4):242–250

    Article  PubMed  PubMed Central  Google Scholar 

  23. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. Br Med J 339:b3692

    Article  CAS  Google Scholar 

  24. Grant WB, Garland CF, Gorham ED (2007) An estimate of cancer mortality rate reductions in Europe and the US with 1000 IU oral vitamin D per day. Recent Results Cancer Res 174:225–234

    Article  CAS  PubMed  Google Scholar 

  25. Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98(7):451–459

    Article  CAS  PubMed  Google Scholar 

  26. Forman JP, Giovannucci E, Holmes MD et al (2007) Plasma 25-Hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49:1063–1069

    Article  CAS  PubMed  Google Scholar 

  27. Pilz S, Dobnig H, Nijpels G et al (2009) Vitamin D and mortality in older men and women. Clin Endocrinol 71:666–672

    Article  CAS  Google Scholar 

  28. Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168(11):1174–1180

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Medicine Io: Dietary Reference Ranges for Calcium and Vitamin D. http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx. 2010

  30. Ross AC, Manson JE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58

    Article  CAS  PubMed  Google Scholar 

  31. Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930

    Article  CAS  PubMed  Google Scholar 

  32. Bolland MJ, Avenell A, Baron JA et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691

    Article  PubMed  PubMed Central  Google Scholar 

  33. Li K, Kaaks R, Linseisen J et al (2012) Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European prospective investigation into cancer and nutrition study (EPIC-Heidelberg). Heart 98:920–925

    Article  CAS  PubMed  Google Scholar 

  34. Verbrugge FH, Gielen E, Milisen K, St B (2012) Who should receive calcium and vitamin D supplementation? Age Ageing 41:576–580

    Article  PubMed  Google Scholar 

  35. Dachverband Osteologie. DVO-Leitlinie 2014 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. http://www.dv-osteologie.org/dvo_leitlinien/osteoporose-leitlinie-2014

  36. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338

    Article  PubMed  Google Scholar 

  37. Rizzoli R, Bonjour JP (2004) Dietary protein and bone health. J Bone Miner Res 19:527–531

    Article  PubMed  Google Scholar 

  38. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Task force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411

    Article  CAS  PubMed  Google Scholar 

  39. Kanis JA, Glüer CC for the Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192–202

    Article  CAS  PubMed  Google Scholar 

  40. Looker AC, Orwoll ES, Johnston CC, Lindsay RL, Wahner HW, Dunn WL et al (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768

    Article  CAS  PubMed  Google Scholar 

  41. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–486

    Article  CAS  PubMed  Google Scholar 

  42. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20(10):1813–1819

    Article  PubMed  Google Scholar 

  43. Schott AM, Cormier C, Hans D, Favier F et al (1998) How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS prospective study. Osteoporos Int 8:247–254

    Article  CAS  PubMed  Google Scholar 

  44. Rizzoli R, Ammann P, Birkhäuser M et al (2009) Au nom de l’Association Suisse Contre l’Ostéoporose (Schweizerische Vereinigung gegen die Osteoporose) Ostéoporose: du diagnostic ostéodensitométrique à l’évaluation du risque absolu de fracture. Schweiz Med Forum 9(36):633–635

    Google Scholar 

  45. Trémollières FA, Pouillès JM, Drewniak N et al (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 25:1002–1009

    Article  PubMed  PubMed Central  Google Scholar 

  46. Leslie WD, Lix LM, Johannson H et al (2011) Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–884

    Article  CAS  PubMed  Google Scholar 

  47. Vasikaran S, Eastell O, Bruyère A et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporo Int 22:391–420

    Article  CAS  Google Scholar 

  48. Delmas PD, Vrijens B, Roux C et al (2003) Reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. ASBMR 2003 [Poster M330]

    Google Scholar 

  49. Baber RJ, Panay N, Fenton A (2016) The IMS writing group 2016 IMS recommendations on Women’s midlife health and menopause hormone therapy. Climacteric 19(2):109–150. doi:10.3109/13697137.2015.1129166

  50. Birkhaeuser M (2014) Primary prevention of fragility fractures in postmenopausal women(part 1): general prevention and primary prevention by MHT Ref. Gynecol Obstet 16:79–110

    Article  Google Scholar 

  51. Wells G, Tugwell P, Shea B et al (2002) A meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529–539

    Article  CAS  PubMed  Google Scholar 

  52. Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet JAMA 2:2891–2897

    Google Scholar 

  53. Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. BMC Musculoskelet Disord 285:7–10

    Article  Google Scholar 

  54. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s health Initiative randomized trial. JAMA 290:1729–1738

    Article  CAS  PubMed  Google Scholar 

  55. Women’ Health Initiative Steering Committee (2004) Effects of conjugated estrogen on postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712

    Article  Google Scholar 

  56. Anderson GL, Hutchinson F, Limacher M, The Women’s Health Initiative Steering Committee et al (2004) The Women’s health initiative randomized controlled trial. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s health initiative controlled trial. JAMA 291:1701–1712

    Article  CAS  PubMed  Google Scholar 

  57. Jackson RD, Wactawski-Wende J, LaCroix AZ et al (2006) Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health Initiative randomized trial. J Bone Miner Res 21:817–828

    Article  CAS  PubMed  Google Scholar 

  58. LaCroix AZ, Chlebowski RT, Manso JAE et al (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. A randomized controlled trial. JAMA 305:1305–1314

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. de Villiers TJ, Hall JE, Pinkerton JV et al (2016) Revised global consensus Statement on menopausal hormone therapy. Climacteric 19:313–315. doi:10.1080/13697137.2016.1196047

    Article  PubMed  Google Scholar 

  60. Birkhäuser MH, Panay N, Archer DF et al (2008) Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 11:108–123

    Article  PubMed  Google Scholar 

  61. NAMS Position Statement (2012) The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 19:257–271

    Article  Google Scholar 

  62. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 287:2668–2676

    Article  CAS  Google Scholar 

  63. Lees B, Stevenson JC (2001) The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17-beta and dydrogesterone. Osteoporos Int 12:251–258

    Article  CAS  PubMed  Google Scholar 

  64. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E, Grady D (2004) Effects of ultralowdose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104:443–451

    Article  CAS  PubMed  Google Scholar 

  65. Greenwald MW, Gluck OS, Lang E, Rakov V (2005) Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 12:741–748

    Article  PubMed  Google Scholar 

  66. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M (2003) Ultra low-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 290:1042–1048

    Article  CAS  PubMed  Google Scholar 

  67. Ettinger B, Genant HK, Steiger P, Madvig P (1992) Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 166:479–488

    Article  CAS  PubMed  Google Scholar 

  68. Huang AJ, Ettinger B, Vittinghoff E, Ensrud KE, Johnson KC, Cummings SR (2007) Endogenous estrogen levels and the effects of ultra-low dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. J Bone Miner Res 22:1791–1797

    Article  CAS  PubMed  Google Scholar 

  69. McClung MR et al (1998) Osteoporosis prevention by low-dose regimens, presented at the ASBRM, San Francisco, PDI/II/USA 1998

    Google Scholar 

  70. Lamy O, Krieg MA, Burckhardt B, Wasserfallen JB (2003) An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women. Expert Opin Pharmacother 4:1479–1488

    Article  PubMed  Google Scholar 

  71. Trémollières FA, Pouilles JM, Ribot C et al (2001) Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 12:385–390

    Article  PubMed  Google Scholar 

  72. Yates J, Barrett-Connor E, Barlas S et al (2004) Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 103:440–446

    Article  CAS  PubMed  Google Scholar 

  73. Mosekilde L, Beck-Nielsen H, Sørensen OH et al (2000) Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women — results of the Danish osteoporosis prevention study. Maturitas 36:181–193

    Article  CAS  PubMed  Google Scholar 

  74. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME, Neer RM (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 93:861–868

    Article  CAS  PubMed  Google Scholar 

  75. Bagger YZ, Tanko LB, Alexandersen P et al (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735

    Article  CAS  PubMed  Google Scholar 

  76. Manson JA, Chlebowski RT, Stefanick ML (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health Initiative randomized trials. JAMA 310:1353–1368

    Article  CAS  PubMed  Google Scholar 

  77. Watts NB, Cauley JA, Jackson RD et al, Women’s Health Initiative Investigators (2016) No increase in fractures after stopping hormone therapy: results from the Women’s health Initiative. J Clin Endocrinol Metab 102:302–308. doi:10.1210/jc.2016-3270

  78. Kloosterboer HL (2011) Historical milestones in the development of tibolone (Livial®). Climacteric 14:609–621

    Article  CAS  PubMed  Google Scholar 

  79. Cummings SR, Ettinger B, Delmas PD et al (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Lippuner K, Haenggi W, Birkhaeuser MH et al (1997) Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-oestradiol and dydrogesterone. J Bone Miner Res 12:806–812

    Article  CAS  PubMed  Google Scholar 

  81. Delmas PD, Davis SR, Hensen S et al (2008) Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int 19:1153–1160

    Article  CAS  PubMed  Google Scholar 

  82. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313–316

    Article  PubMed  Google Scholar 

  83. Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293–300

    Article  CAS  PubMed  Google Scholar 

  84. Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735

    Article  CAS  PubMed  Google Scholar 

  85. Miller P et al (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535

    Article  CAS  PubMed  Google Scholar 

  86. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934

    Article  CAS  PubMed  Google Scholar 

  87. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054

    Article  CAS  PubMed  Google Scholar 

  88. Silverman SL, Chines AA, Kendler DL et al (2012) Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporosis Int 23:351–363

    Article  CAS  Google Scholar 

  89. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G (2009) Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92:1045–1052

    Article  CAS  PubMed  Google Scholar 

  90. Birkhaeuser M (2016) Primary prevention of fragility fractures in postmenopausal women (part 2): non-hormonal antiresorptive therapies and osteo-anabolic treatment. Ref Gynecol Obstet 17:30–73

    Google Scholar 

  91. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  92. Black DM, Cummings SR, Karpf DB et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  93. Cranney A, Wells G, Willan A et al (2002) II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516

    Article  CAS  PubMed  Google Scholar 

  94. Wells G, Cranney A, Peterson J et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD004523

    Google Scholar 

  95. Rossini M, Idolazzi L, Adami S (2011) Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review. Ther Adv Musculoskel Dis 3:67–79

    Article  CAS  Google Scholar 

  96. Rizzoli R (2010) Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskel Dis 2:3–16

    Article  CAS  Google Scholar 

  97. Shane E, Burr D, Abrahamsen B et al (2014) Atypical sub-trochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  PubMed  Google Scholar 

  98. Rizzoli R, Reginster J-Y, Boonen S et al (2011) Adverse reactions and drug–drug interactions in the Management of Women with postmenopausal osteoporosis. Calcif Tissue Int 89:91–104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: a report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Papapoulos S, Lippuner K, Roux C et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773–2783. doi:10.1007/s00198-015-3234-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Reid IR (2015) Denosumab after 8 years. Editorial Osteoporos Int 26:2759–2761

    Article  CAS  PubMed  Google Scholar 

  102. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX(R). J Bone Miner Res 27:1480–1486. doi:10.1002/jbmr.1606

    Article  CAS  PubMed  Google Scholar 

  103. von Keyserlingk C, Hopkins R, Anastasilakis A et al (2011) Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum 41:178–186

    Article  Google Scholar 

  104. McClung MR (2016) Cancel the denosumab holiday. Osteoporos Int 27(5):1677–1682

    Article  CAS  PubMed  Google Scholar 

  105. Meunier PJ, Roux C, Ortolani S et al (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 20:1663–1673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Reginster J-Y, Kaufman J-M, Goemare S et al (2012) Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 23:1115–1122

    Article  CAS  PubMed  Google Scholar 

  107. European Medicine Agency (15 Apr 2014) Protelos/Osseor to remain available but with further restrictions. EMA/235924/2014

    Google Scholar 

  108. Meier C, Lamy O, Krieg M-A, Mellinghoff H-U, Felder M, Ferrari S, Rizzoli R (2014) The role of teriparatide in sequential and combination therapy of osteoporosis. Swiss Med Wkly 144:w13952

    PubMed  Google Scholar 

  109. Kraenzlin ME, Meier C (2011) Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7:647–656. doi:10.1038/nrendo.2011.108

    Article  CAS  PubMed  Google Scholar 

  110. Expertenbrief der SGGG No 28 (2015) Aktuelle Empfehlungen zur menopausalen Hormon-Therapie (MHT) (www.sggg.ch/ im Druck, 2015)

  111. Baber R.J. et al., Climacteric 2016; 19 (2): 109–150; doi:10.3109/13697137.2015.1129166

Download references

Author information

Author notes

  1. Martin Birkhaeuser

    Present address: , Gartenstrasse 67, CH-4052, Basel, Switzerland

Authors and Affiliations

  1. Professor emeritus for Gynaecological Endocrinology and Reproductive Medicine, University of Bern, Bern, Switzerland

    Martin Birkhaeuser

Authors
  1. Martin Birkhaeuser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Birkhaeuser .

Editor information

Editors and Affiliations

  1. Professor emeritus for Gynaecological Endocrinology and Reproductive Medicine, University of Bern, Bern, Switzerland

    Martin Birkhaeuser

  2. International Society of Gynecological Endocrinology, Pisa, Italy

    Andrea R. Genazzani

Rights and permissions

Reprints and permissions

Copyright information

© 2018 International Society of Gynecological Endocrinology

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Birkhaeuser, M. (2018). Healthy Bones After Menopause: What Has to Be Done?. In: Birkhaeuser, M., Genazzani, A. (eds) Pre-Menopause, Menopause and Beyond. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-63540-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63540-8_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63539-2

  • Online ISBN: 978-3-319-63540-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation